Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
292 studies found for:    Thrombocytopenia: Clinical Trials
Show Display Options
Rank Status Study
21 Not yet recruiting Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia
Conditions: Adult Immune Thrombocytopenia (ITP);   Dapsone
Interventions: Drug: Dapsone (Disulone®);   Drug: Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";   Drug: Prednisone (Cortancyl®)
22 Recruiting A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Eltrombopag;   Drug: IVIG infusion
23 Completed An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia
Condition: Immune Thrombocytopenia
Intervention: Drug: Human immunoglobulin intravenous
24 Enrolling by invitation A Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Cancer
Condition: Gynecologic Cancer
Interventions: Drug: Eltrombopag;   Drug: Placebo
25 Completed Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Condition: Antiphospholipid (aPL)-Positive
Intervention: Biological: Study Drug- ALXN1007
26 Completed
Has Results
Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Condition: Thrombocytopenia
Interventions: Procedure: Medium Dose Prophylactic Platelet Transfusions;   Procedure: Lower Dose Prophylactic Platelet Transfusions;   Procedure: Higher Dose Prophylactic Platelet Transfusions
27 Terminated Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)
Conditions: Chronic Lymphocytic Leukemia;   Thrombocytopenia
Interventions: Drug: Placebo;   Drug: Eltrombopag
28 Recruiting Observational Trial of a Therapeutic Platelet Transfusion Regimen
Conditions: Acute Myeloid Leukemia;   Thrombocytopenia
Intervention:
29 Completed
Has Results
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
30 Completed
Has Results
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Condition: Atypical Hemolytic-Uremic Syndrome
Intervention: Drug: Eculizumab
31 Terminated
Has Results
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
Condition: Heparin-Induced Thrombocytopenia
Interventions: Drug: fondaparinux;   Drug: warfarin
32 Terminated A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
Condition: Chemotherapy-Induced Thrombocytopenia
Intervention: Drug: ONO-7746
33 Completed PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
Conditions: Critical Illness;   Deep Venous Thrombosis
Interventions: Drug: LMWH (Fragmin, dalteparin);   Drug: Unfractionated Heparin
34 Completed Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
Conditions: Chronic Thrombocytopenia;   Immune Thrombocytopenia
Interventions: Drug: Avatrombopag;   Drug: Placebo;   Drug: Standard of care
35 Withdrawn Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Interventions: Drug: Dexamethasone (4 cycles);   Drug: Dexamethasone (1 cycle)
36 Unknown  Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Conditions: Purpura, Thrombocytopenic, Idiopathic;   Autoimmune Thrombocytopenic Purpura;   Autoimmune Thrombocytopenia;   Chronic Lymphocytic Leukemia;   Non Hodgkin's Lymphoma
Intervention: Drug: Eltrombopag Olamine
37 Terminated Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Thrombocytopenia
Intervention: Biological: romiplostim
38 Completed PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)
Conditions: Critically Ill;   Deep Venous Thrombosis
Intervention: Drug: Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)
39 Completed
Has Results
Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
Condition: Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Interventions: Drug: lepirudin;   Drug: danaparoid;   Drug: argatroban;   Drug: fondaparinux
40 Completed Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days
Condition: Thrombocytopenia
Intervention: Device: Transfusion of Pathogen Inactivated Platelets stored for 6-7 days

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.